A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

Paclitaxel (7 day)

Description
Chemotherapy Protocol BREAST CANCER PACLITAXEL (7 day) Regimen • Breast Cancer – Paclitaxel (7 day) Indication • Treatment of locally advanced or metastatic breast
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Paclitaxel-7-day.pdf

Paclitaxel (7 day)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER PACLITAXEL (7 day) Regimen • Ovary – Paclitaxel (7 day) Indication • Second or subsequent line treatment of platinum refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Paclitaxel-7-day.pdf

Liposomal doxorubicin

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER LIPOSOMAL DOXORUBICIN (Caelyx) Please note this protocol is based on information for the use of the Caelyx
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Liposomaldoxorubicin.pdf

Irinotecan Mitomycin

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER IRINOTECAN-MITOMYCIN Regimen Ovary-Irinotecan-Mitomycin Indication Platinum refractory clear cell or mucinous ovarian cancer Recurrent platinum
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/IrinotecanMitomycin.pdf

Cisplatin Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (Oral) Regimen Ovary-Cisplatin-Etoposide PO Indication Treatment of partially platinum-sensitive or platinum-refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CisplatinEtoposidePO.pdf

Bevacizumab (15mgkg)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (15) This protocol may require funding Regimen Ovary-Bevacizumab (15) Indication Recurrent platinum sensitive ovarian, peritoneal
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Bevacizumab15mgkg.pdf

Cisplatin and Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (oral) Regimen Uterine-Cisplatin-Etoposide PO Indication Treatment of partially platinum-sensitive or platinum-refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/CisplatinEtoposidePO.pdf

Cisplatin and Topotecan

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-TOPOTECAN (intravenous) Regimen Cervix-Cisplatin-Topotecan IV Indication Recurrent stage IVB cervical cancer in patients who
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/CisplatinandTopotecan.pdf

Cisplatin and Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (oral) Regimen Cervix-Cisplatin-Etoposide PO Indication Treatment of partially platinum-sensitive or platinum-refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/CisplatinandEtoposidePO.pdf

Cisplatin (40) and Radiotherapy

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN (40)-RADIOTHERAPY Regimen Cervix-Cisplatin (40)-Radiotherapy Indication Locally advanced cervical, vaginal and vulval cancer with
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/Cisplatin40andRadiotherapy.pdf
471 to 480 of 734
Previous … 46 47 48 49 50 … Next